Table of Contents
To view the fulltext, log-in or choose pay-per-view options:
Get Access

Hidradenitis Suppurativa and Zinc: A New Therapeutic Approach

A Pilot Study Brocard A.a · Knol A.-C.b · Khammari A.a · Dréno B.a
aDepartment of Dermatology and bLaboratory of Dermato-Immunology, INSERM U601, CHU Hôtel-Dieu, Nantes, France Dermatology 2007;214:325–327 (DOI:10.1159/000100883)

Abstract

Background: Hidradenitis suppurativa (Verneuil’s disease) is a chronic suppurative dermatosis involving apocrine glands with a severe impact on the quality of life, which is enhanced by the fact that the drugs usually prescribed are poorly effective. Objective: We discuss a new therapeutic approach based on zinc salts. Methods: We performed a pilot study on 22 patients, mainly from grade I or II in Hurley’s classification. All included patients had previously been prescribed a treatment (antibiotic, isotretinoin, surgery or anti-androgens), which was inefficient. They were then treated with 90 mg of zinc gluconate per day (15 mg zinc per Rubozinc® capsule). Results: We observed a clinical response in all patients, with 8 complete remissions (CR) and 14 partial remissions (PR). When CR was obtained, the treatment was progressively decreased (average of 3.5 capsules/day); 4/22 patients experienced side-effects, mainly gastro-intestinal. Conclusion: Zinc salts could provide a new therapeutic alternative for the treatment of hidradenitis suppurativa.

 

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.


Pay-per-View Options
Direct payment This item at the regular price: USD 33.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00